Longitudinal MR-based proton-density fat fraction (PDFF) and T2* for the assessment of associations between bone marrow changes and myelotoxic chemotherapy.
Felix G GassertJulia KranzFlorian T GassertBenedikt J SchwaigerChristian BognerMarcus R MakowskiLeander GlanzJonathan StelterThomas BaumRickmer BrarenDimitrios C KarampinosAlexandra S GersingPublished in: European radiology (2023)
Quantifying changes in bone marrow fat fraction, as well as T2* caused by myelotoxic pharmaceuticals using proton density fat fraction, is feasible. Proton density fat fraction could potentially be established as a non-invasive biomarker for early bone marrow changes in oncologic patients undergoing myelotoxic treatment.